Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of August 3, 2025 • 8:00 PM ET

Date/Time Source News Release
07/30/2025 07:00 AM EDT GlobeNewswire Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
06/23/2025 07:00 AM EDT GlobeNewswire Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
06/17/2025 07:00 AM EDT GlobeNewswire Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
05/22/2025 07:00 AM EDT GlobeNewswire Skye Bioscience to Participate in Upcoming Investment Conferences
05/19/2025 05:00 AM EDT GlobeNewswire Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
05/13/2025 04:05 PM EDT GlobeNewswire Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/13/2025 07:00 AM EDT GlobeNewswire Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
05/08/2025 04:01 PM EDT GlobeNewswire Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
05/07/2025 07:00 AM EDT GlobeNewswire Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
04/29/2025 07:00 AM EDT GlobeNewswire Skye Bioscience to Participate in May Investment and Medical Conferences
Page

Additional News

As of August 3, 2025 • 8:00 PM ET

Date/Time Source News Release
06/23/2025 02:30 PM EDT PRISM News PRISM Mid-Day Movers: Psychedelic Milestone and Weight Loss Fallout Shake Indexes
06/19/2025 08:22 AM EDT SeekingAlpha Skye confirms phase 2 data on nimacimab for obesity expected later this year
05/23/2025 11:13 AM EDT Zacks 3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
05/19/2025 12:01 PM EDT PRISM News Skye Bioscience and Arecor Partner to Advance High-Concentration Formulation of Obesity Drug Candidate
05/10/2025 05:31 AM EDT US Earnings Reports Expected earnings - Skye Bioscience Inc.
05/09/2025 07:20 PM EDT SeekingAlpha Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript
05/08/2025 05:25 PM EDT SeekingAlpha Skye Bioscience GAAP EPS of -$0.28 beats by $0.01
04/16/2025 07:50 AM EDT SeekingAlpha A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value
04/15/2025 10:34 AM EDT 24/7 Market News Today's Top News and Trades- SKYE, KBLB, MTVA, ARBB, MURA, SNYR
03/20/2025 09:59 PM EDT SeekingAlpha Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.